Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2004 3
2005 5
2006 1
2008 2
2009 3
2010 2
2011 5
2012 7
2013 1
2014 2
2015 3
2017 5
2018 4
2019 2
2020 18
2021 12
2022 16
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean alexandros, spyridonidis (4 results)?
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji RM, Griskevicius L, Salmenniemi U, Rambaldi A, Mielke S, Kulagin A, Passweg J, Luft T, Gedde-Dahl T, Forcade E, Helbig G, Stelljes M, Castilla-Llorente C, Spyridonidis A, Brissot E, Ciceri F, Mohty M. Nagler A, et al. Among authors: spyridonidis a. Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284-5. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38615143
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474. Online ahead of print. J Clin Oncol. 2024. PMID: 38471061
Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT.
Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, Tischer J, Chevallier P, Bramanti S, Fanin R, Socié G, Forcade E, Kröger N, Koc Y, Itälä-Remes M, Zecca M, Nagler A, Brissot E, Spyridonidis A, Bazarbachi A, Giebel S, Piemontese S, Mohty M, Ciceri F. Sanz J, et al. Among authors: spyridonidis a. Blood Adv. 2024 Mar 1:bloodadvances.2023012133. doi: 10.1182/bloodadvances.2023012133. Online ahead of print. Blood Adv. 2024. PMID: 38429091
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Craddock C, Raj K, Bloor A, Nicholson E, Eder M, Kim O, Valerius T, Snowden JA, Tholouli E, Crawley C, Collin M, Wilson KMO, Gadisseur A, Protheroe R, Wagner-Drouet EM, Savani BN, Spyridonidis A, Ciceri F, Nagler A, Mohty M. Duque-Afonso J, et al. Among authors: spyridonidis a. Bone Marrow Transplant. 2024 Feb;59(2):247-254. doi: 10.1038/s41409-023-02150-w. Epub 2023 Dec 2. Bone Marrow Transplant. 2024. PMID: 38040842 Free PMC article.
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation.
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet EM, Versluis J, Schroeder T, Blau IW, Wulf GG, Dreger P, Olesen G, Sengeloev H, Kröger N, Potter V, Forcade E, Passweg J, de Latour RP, Maertens J, Wilson KMO, Bourhis JH, Finke J, Brissot E, Bazarbachi A, Giebel S, Savani BP, Nagler A, Ciceri F, Mohty M. Spyridonidis A, et al. Bone Marrow Transplant. 2024 Feb;59(2):217-223. doi: 10.1038/s41409-023-02139-5. Epub 2023 Nov 17. Bone Marrow Transplant. 2024. PMID: 37978322 Free PMC article.
A GMP-Compliant Procedure for the Generation of Gene-Modified T cells.
Savvopoulos N, Stampolitis K, Alexandropoulos G, Kefala D, Lysandrou M, Zacharioudaki V, Tsolakos N, Spyridonidis A. Savvopoulos N, et al. Among authors: spyridonidis a. J Vis Exp. 2023 Oct 6;(200). doi: 10.3791/65097. J Vis Exp. 2023. PMID: 37870303
Hypomethylation-induced regulatory programs in T cells unveiled by transcriptomic analyses.
Lysandrou M, Stamou P, Kefala D, Pierides C, Kyriakou M, Savvopoulos N, Christofi P, Papadopoulou A, Yannaki E, Costeas P, Spyridonidis A. Lysandrou M, et al. Among authors: spyridonidis a. Front Immunol. 2023 Sep 27;14:1235661. doi: 10.3389/fimmu.2023.1235661. eCollection 2023. Front Immunol. 2023. PMID: 37828996 Free PMC article.
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia G, Labopin M, Mielke S, Ruggeri A, Nur Ozkurt Z, Bourhis JH, Rabitsch W, Yakoub-Agha I, Grillo G, Sanz J, Arcese W, Novis Y, Fegueux N, Spyridonidis A, Giebel S, Nagler A, Ciceri F, Mohty M. Battipaglia G, et al. Among authors: spyridonidis a. Transplant Cell Ther. 2024 Jan;30(1):95.e1-95.e10. doi: 10.1016/j.jtct.2023.09.028. Epub 2023 Oct 8. Transplant Cell Ther. 2024. PMID: 37816471 Free article.
Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT.
Saraceni F, Labopin M, Raiola AM, Blaise D, Reményi P, Sorà F, Pavlu J, Bramanti S, Busca A, Berceanu A, Battipaglia G, Visani G, Sociè G, Bug G, Micò C, La Nasa G, Musso M, Olivieri A, Spyridonidis A, Savani B, Ciceri F, Nagler A, Mohty M. Saraceni F, et al. Among authors: spyridonidis a. Hemasphere. 2023 Sep 20;7(10):e952. doi: 10.1097/HS9.0000000000000952. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37746158 Free PMC article.
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S, Labopin M, Salmenniemi U, Socié G, Bondarenko S, Blaise D, Kröger N, Vydra J, Grassi A, Bonifazi F, Czerw T, Anagnostopoulos A, Lioure B, Ruggeri A, Savani B, Spyridonidis A, Sanz J, Peric Z, Nagler A, Ciceri F, Mohty M. Giebel S, et al. Among authors: spyridonidis a. Cancer. 2023 Dec 1;129(23):3735-3745. doi: 10.1002/cncr.35004. Epub 2023 Sep 1. Cancer. 2023. PMID: 37658621
97 results